Table 1.
Patient characteristics at the time of first progression/relapse
| PTCL-NOS | AITL | ||
|---|---|---|---|
| N | 135 | 105 | |
| Median age, years | (range) | 55 (23–79) | 64 (28–83) |
| Gender | Male | 93 (69) | 56 (53) |
| Performance status | 2–4 | 28 (29) | 17 (22) |
| Stage | 3–4 | 75 (78) | 72 (92) |
| Lactate dehydrogenase | Above normal | 46 (48) | 34 (44) |
| Bone marrow involvement | Present | 40 (42) | 34 (44) |
| Albumin | Median (range) | 3.8 (1.3–4.8) | 3.9 (1.8–4.9) |
| Beta-2 microglobulin | Median (range) | 3.6 (1.6–12.4) | 3.7 (1.7–9.3) |
| First line chemotherapy | CHOP | 79 (56) | 80 (76) |
| Etoposide-containing regimen | 17 (16) | 10 (9) | |
| HCVAD, HCVIDD | 26 (19) | 9 (9) | |
| Others | 13 (9) | 6 (6) | |
| Prior stem cell transplant | Autologous/Allogeneic | 10/1 | 8/0 |
| Duration of response to first line therapy | < 6 months | 69 (51) | 24 (23) |
| 6 – 12 months | 42 (31) | 39 (37) | |
| ≥ 12 months | 24 (18) | 42 (40) | |
| International Prognostic Index | Low | 32 (33) | 12 (16) |
| Low-Intermediate | 23 (24) | 34 (45) | |
| Intermediate-High | 26 (27) | 20 (26) | |
| High | 15 (16) | 10 (13) | |
| PIT | Group 1 | 13 (14) | 6 (8) |
| Group 2 | 34 (35) | 28 (36) | |
| Group 3 | 28 (29) | 28 (36) | |
| Group 4 | 21 (22) | 15 (20) | |
| Response to first line therapy | CR | 51 (38) | 62 (59) |
| PR | 25 (19) | 16 (15) | |
| SD/PD | 53 (39) | 25 (24) | |
AITL, angioimmunoblastic T-cell lymphoma; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; CR, complete response, HCVAD, hyper-fractionated cyclophosphamide, vincristine, dexamethasone, doxorubicin; HCVIDD, hyper-fractionated cyclophosphamide, vincristine, dexamethasone, liposomal doxorubicin; PD, progressive disease; PIT, prognostic index for PTCL-NOS; PR, partial response; PTCL-NOS, peripheral T-cell lymphoma-not otherwise specified; SD, stable disease